MENLO PARK, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, announced today the addition of Ian Clements, Ph.D., to the company's leadership team as vice president, investor relations.
Dr. Clements brings over 20 years of industry experience to Dermira. Most recently, he led investor relations and corporate communications at Tobira Therapeutics, Inc., which was acquired by Allergan plc. Previously, he led investor relations and corporate communications at Avanir Pharmaceuticals, Inc., until its acquisition by Otsuka Pharmaceutical Co., Ltd. Dr. Clements also held positions at Sequenom, Inc., the Trout Group LLC, an investor relations agency, and Accelrys, Inc. He holds a Ph.D. in Chemistry from the University of Manchester and an M.B.A. from the Open University in the U.K.
"I am delighted to welcome Ian to the Dermira team," said Andrew Guggenhime, chief operating officer and chief financial officer of Dermira. "Ian's extensive experience in investor relations will be critical as we work to expand our outreach to and presence with the investment and financial communities."
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s product pipeline includes three late-stage product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate (formerly DRM04), which has completed a Phase 3 program for the treatment of primary axillary hyperhidrosis (excessive underarm sweating); CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe chronic plaque psoriasis; and olumacostat glasaretil (formerly DRM01), in Phase 3 development for the treatment of acne vulgaris. Dermira is headquartered in Menlo Park, Calif. For more information, please visit www.dermira.com.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com) and LinkedIn page (https://www.linkedin.com/company/dermira-inc-) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website and LinkedIn page in addition to following its SEC filings, press releases, public conference calls and webcasts.
Senior Director, Head of Corporate Communications
Ian Clements, Ph.D.
Vice President, Investor Relations
Robert H. Uhl